Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Layered on Darolutamide in Oligoprogressive CRPC
NCT04070209Phase 2Active, not recruiting
- Sponsor
- Jewish General Hospital
- Start
- Oct 2020
- Primary completion
- Nov 2030
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in castration-resistant prostate cancer (CRPC), sponsored by Jewish General Hospital. Started Oct 2020; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04070209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04070209.